Sitemap
Posts
- Category: Adrenal
- Cortisol in Fetal Fluids and the Fetal Adrenal at Parturition in the Tammar Wallaby (Macropus eugenii )(1)
- Cortisol in Fetal Fluids and the Fetal Adrenal at Parturition in the Tammar Wallaby (Macropus eugenii )(2)
- Cortisol in Fetal Fluids and the Fetal Adrenal: DISCUSSION(1)
- Cortisol in Fetal Fluids and the Fetal Adrenal: DISCUSSION(2)
- Cortisol in Fetal Fluids and the Fetal Adrenal: DISCUSSION(3)
- Cortisol in Fetal Fluids and the Fetal Adrenal: MATERIALS AND METHODS(1)
- Cortisol in Fetal Fluids and the Fetal Adrenal: MATERIALS AND METHODS(2)
- Cortisol in Fetal Fluids and the Fetal Adrenal: MATERIALS AND METHODS(3)
- Cortisol in Fetal Fluids and the Fetal Adrenal: RESULTS
- Category: Antibiotics
- Category: Asthma
- Brief look at Levaquin
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Comment
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Conclusion
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Discussion
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Materials and Methods
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Recommendation
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Research
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Results
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Statistical Methods
- Effects of Early Intervention With Inhaled Budesonide on Lung Function in Newly Diagnosed Asthma: Summary
- How to stop an asthma attack without relievers
- Production of nitric oxide and prostacyclin in acetylsalicylic acid-induced asthma (part 1)
- Production of nitric oxide and prostacyclin in acetylsalicylic acid-induced asthma (part 2)
- Production of nitric oxide and prostacyclin in acetylsalicylic acid-induced asthma (part 3)
- Production of nitric oxide and prostacyclin in acetylsalicylic acid-induced asthma (part 4)
- Production of nitric oxide and prostacyclin in acetylsalicylic acid-induced asthma (part 5)
- Category: Birth control
- Category: Bovine Oocytes
- Maintenance of Bovine Oocytes in Meiotic Arrest and Subsequent Development In Vitro(1)
- Maintenance of Bovine Oocytes in Meiotic Arrest and Subsequent Development In Vitro(2)
- Maintenance of Bovine Oocytes in Meiotic Arrest and Subsequent Development In Vitro(3)
- Maintenance of Bovine Oocytes: DISCUSSION(1)
- Maintenance of Bovine Oocytes: DISCUSSION(2)
- Maintenance of Bovine Oocytes: DISCUSSION(3)
- Maintenance of Bovine Oocytes: DISCUSSION(4)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(1)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(2)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(3)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(4)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(5)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(6)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(7)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(8)
- Maintenance of Bovine Oocytes: MATERIALS AND METHODS(9)
- Maintenance of Bovine Oocytes: RESULTS(1)
- Maintenance of Bovine Oocytes: RESULTS(2)
- Maintenance of Bovine Oocytes: RESULTS(3)
- Category: Cardiology
- Acute Reversible Cardiomyopathy Associated With the Systemic Inflammatory Response Syndrome - Case Report
- Acute Reversible Cardiomyopathy Associated With the Systemic Inflammatory Response Syndrome - Discussion
- Acute Reversible Cardiomyopathy Associated With the Systemic Inflammatory Response Syndrome - Results
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 1)
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 2)
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 3)
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 4)
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 5)
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 6)
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 7)
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 8)
- Comparison of disopyramide, propafenone and sotalol after direct current cardioversion of chronic atrial fibrillation (part 9)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 1)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 10)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 11)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 12)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 13). DISCUSSION
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 14)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 15)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 2)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 3). MATERIALS AND METHODS
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 4)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 5)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 6)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 7)
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 8). RESULTS
- Computational study of the impact of cardiac mechanosensitive fibroblasts on heart rhythm (part 9)
- Transcellular synthesis of cysteinyl-leukotrienes: From isolated cells to complex organ system (part 1)
- Transcellular synthesis of cysteinyl-leukotrienes: From isolated cells to complex organ system (part 2)
- Transcellular synthesis of cysteinyl-leukotrienes: From isolated cells to complex organ system (part 3)
- Transcellular synthesis of cysteinyl-leukotrienes: From isolated cells to complex organ system (part 4)
- Category: chest pain
- Category: Children and adolescents
- Informed consent in children and adolescents
- Informed consent in children and adolescents: AGE OF MAJORITY VERSUS AGE NECESSARY FOR INFORMED CONSENT
- Informed consent in children and adolescents: CAPACITY AND INFORMED CONSENT (part 1)
- Informed consent in children and adolescents: CAPACITY AND INFORMED CONSENT (part 2)
- Informed consent in children and adolescents: CASE LAW EXAMPLES
- Informed consent in children and adolescents: CONCLUSION (part 1)
- Informed consent in children and adolescents: CONCLUSION (part 2)
- Informed consent in children and adolescents: PROVINCIAL LEGISLATION (part 1)
- Informed consent in children and adolescents: PROVINCIAL LEGISLATION (part 2)
- Informed consent in children and adolescents: PROVINCIAL LEGISLATION (part 3)
- Informed consent in children and adolescents: PROVINCIAL LEGISLATION (part 4)
- Informed consent in children and adolescents: REFUSAL OF CONSENT OR INCAPACITY (part 1)
- Informed consent in children and adolescents: REFUSAL OF CONSENT OR INCAPACITY (part 2)
- Category: COPD
- Canadian Health&Care Mall: Results of Airway Inflammation During Severe Exacerbations of COPD
- Details about The 6-Min Walk Distance, Peak Oxygen Uptake, and Mortality in COPD
- My Canadian Pharmacy: The 6-Min Walk Distance, Peak Oxygen Uptake, and Mortality in COPD
- Research of The 6-Min Walk Distance, Peak Oxygen Uptake, and Mortality in COPD
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Assessment of Skin Changes
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: CFC
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Discussion
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Easy Bruising
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: ICS therapy
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: LHS
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Materials and Methods
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Results
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Slow Healing
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: The effect of compliance
- Skin Manifestations of Inhaled Corticosteroids in COPD Patients: The ICS group
- Category: Emphysema
- Advanced Emphysema in African-American and White Patients
- Advanced Emphysema in African-American and White Patients: Conclusion
- Advanced Emphysema in African-American and White Patients: Demographic and Physiologic Racial Differences
- Advanced Emphysema in African-American and White Patients: Discussion
- Advanced Emphysema in African-American and White Patients: Discussion
- Advanced Emphysema in African-American and White Patients: Patient Data
- Advanced Emphysema in African-American and White Patients: Patient Selection
- Advanced Emphysema in African-American and White Patients: Results
- Advanced Emphysema in African-American and White Patients: Statistical Analysis
- Category: Erectile Dysfunction
- Category: Escherichia coli O157:H7
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: part 1
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: part 2
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: part 3
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: part 4
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: part 5
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: part 6
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: part 7
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: PREVENTION
- Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood: RECOMMENDATIONS
- NFORMATION FOR SHARING WITH PARENTS AND FAMILIES HAMBURGER DISEASE OR BARBECUE SYNDROME VTEC GASTROENTERITIS: part 1
- NFORMATION FOR SHARING WITH PARENTS AND FAMILIES HAMBURGER DISEASE OR BARBECUE SYNDROME VTEC GASTROENTERITIS: part 2
- Category: Fatal aplastic
- Fatal aplastic anemia associated with ticlopidine therapy - Approaches to an adverse drug reaction: CASE DESCRIPTION
- Fatal aplastic anemia associated with ticlopidine therapy - Approaches to an adverse drug reaction: COMMENTS(1)
- Fatal aplastic anemia associated with ticlopidine therapy - Approaches to an adverse drug reaction: COMMENTS(2)
- Fatal aplastic anemia associated with ticlopidine therapy - Approaches to an adverse drug reaction: CONCLUSIONS
- Fatal aplastic anemia associated with ticlopidine therapy - Approaches to an adverse drug reaction:COMMENTS(3)
- Category: Follicles
- Distribution of the «1 to «6 Chains of Type IV Collagen in Bovine Follicles(1)
- Distribution of the «1 to «6 Chains of Type IV Collagen in Bovine Follicles(2)
- Distribution of the «1 to «6 Chains of Type IV Collagen in Bovine Follicles(3)
- Distribution of the «1 to «6 Chains of Type IV Collagen: DISCUSSION(1)
- Distribution of the «1 to «6 Chains of Type IV Collagen: DISCUSSION(2)
- Distribution of the «1 to «6 Chains of Type IV Collagen: DISCUSSION(3)
- Distribution of the «1 to «6 Chains of Type IV Collagen: DISCUSSION(4)
- Distribution of the «1 to «6 Chains of Type IV Collagen: DISCUSSION(5)
- Distribution of the «1 to «6 Chains of Type IV Collagen: DISCUSSION(6)
- Distribution of the «1 to «6 Chains of Type IV Collagen: DISCUSSION(7)
- Distribution of the «1 to «6 Chains of Type IV Collagen: MATERIALS AND METHODS(1)
- Distribution of the «1 to «6 Chains of Type IV Collagen: MATERIALS AND METHODS(2)
- Distribution of the «1 to «6 Chains of Type IV Collagen: MATERIALS AND METHODS(3)
- Distribution of the «1 to «6 Chains of Type IV Collagen: MATERIALS AND METHODS(4)
- Distribution of the «1 to «6 Chains of Type IV Collagen: MATERIALS AND METHODS(5)
- Distribution of the «1 to «6 Chains of Type IV Collagen: MATERIALS AND METHODS(6)
- Distribution of the «1 to «6 Chains of Type IV Collagen: MATERIALS AND METHODS(7)
- Distribution of the «1 to «6 Chains of Type IV Collagen: MATERIALS AND METHODS(8)
- Distribution of the «1 to «6 Chains of Type IV Collagen: RESULTS(1)
- Distribution of the «1 to «6 Chains of Type IV Collagen: RESULTS(2)
- Distribution of the «1 to «6 Chains of Type IV Collagen: RESULTS(3)
- Distribution of the «1 to «6 Chains of Type IV Collagen: RESULTS(4)
- Distribution of the «1 to «6 Chains of Type IV Collagen: RESULTS(5)
- Category: Gallbladder
- Gallbladder polyps: CLINICAL MANAGEMENT OF GALLBLADDER POLYPS Part 1
- Gallbladder polyps: CLINICAL MANAGEMENT OF GALLBLADDER POLYPS Part 2
- Gallbladder polyps: CLINICAL SIGNIFICANCE OF GALLBLADDER POLYPS Part 1
- Gallbladder polyps: CLINICAL SIGNIFICANCE OF GALLBLADDER POLYPS Part 2
- Gallbladder polyps: CLINICAL SIGNIFICANCE OF GALLBLADDER POLYPS Part 3
- Gallbladder polyps: CONCLUSIONS
- Gallbladder polyps: Epidemiology, natural history and management
- Gallbladder polyps: NATURAL HISTORY OF PLG Part 1
- Gallbladder polyps: NATURAL HISTORY OF PLG Part 2
- Gallbladder polyps: PREVALENCE
- Gallbladder polyps: RADIOLOGICAL ASSESSMENT OF GALLBLADDER POLYPS Part 1
- Gallbladder polyps: RADIOLOGICAL ASSESSMENT OF GALLBLADDER POLYPS Part 2
- Gallbladder polyps: RISK FACTORS FOR GALLBLADDER POLYPS Part 1
- Gallbladder polyps: RISK FACTORS FOR GALLBLADDER POLYPS Part 2
- Category: Growth Factor
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor Signaling Pathways(1)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor Signaling Pathways(2)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ER LIGAND-INDEPENDENT ACTIVATION(1)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ER LIGAND-INDEPENDENT ACTIVATION(2)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ER LIGAND-INDEPENDENT ACTIVATION(3)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ER LIGAND-INDEPENDENT ACTIVATION(4)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ER PHOSPHORYLATION(1)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ER PHOSPHORYLATION(2)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ESTROGEN RESPONSES(1)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ESTROGEN RESPONSES(2)
- Cross-Talk between Peptide Growth Factor and Estrogen Receptor: ESTROGEN RESPONSES(3)
Plugin by dagondesign.com